How psychological safety influences workplace injury prevention and offers strategies for safety professionals to foster more ...

The National Safety Council is urging construction employers and safety professionals nationwide to participate in the 2025 ...

Employers nationwide are encouraged to pause work during the week of May 5–9 to raise awareness and prevent deadly falls in ...

Too often, safety in construction is treated like a seasonal campaign—something to highlight for a week, reference during a ...

Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA breakthrough therapy designation, underway in post-bariatric hypoglycemia (PBH); completion ...

Q1 2025 Earnings Call Transcript May 12, 2025 UroGen Pharma Ltd. misses on earnings expectations. Reported EPS is $-0.92 EPS, ...

Atea defines working capital as current assets less current liabilities. See the Company's condensed consolidated financial ...

Credicorp's BCP leads Peru's banking sector with strong ROE, leveraging market share and low-cost deposits. See an analysis ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

Welcome to the Legend Biotech’s First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescr ...

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Annou ...